P-Glycoprotein Involvement in Sertraline Pharmacokinetics
Yes, P-glycoprotein (P-gp) is significantly involved in sertraline's pharmacokinetics and CNS distribution, with sertraline and its active metabolite desmethylsertraline demonstrating high affinity for P-gp comparable to the prototypical P-gp substrate verapamil. 1
Direct Evidence of P-gp Interaction
Sertraline shows high-affinity binding to P-gp with kinetic parameters (Vmax/Km = 1.6 min⁻¹ × 10⁻³) essentially identical to verapamil (1.7 min⁻¹ × 10⁻³), the classic P-gp substrate. 1 This indicates that sertraline is actively transported by P-gp at the blood-brain barrier, which can limit its CNS penetration. Desmethylsertraline, the primary active metabolite, exhibits similarly high P-gp affinity (Vmax/Km = 1.4 min⁻¹ × 10⁻³). 1
Complex Tissue-Specific Effects
The interaction between sertraline and P-gp demonstrates tissue-specific and time-dependent modulation that differs from simple substrate behavior:
Blood-Brain Barrier Effects
- Sertraline produces a biphasic effect on P-gp function at the BBB: initial inhibition at 5 minutes (increasing brain accumulation of co-administered P-gp substrates), followed by enhanced P-gp activity at 60 minutes (decreasing brain accumulation), then returning to increased accumulation by 240 minutes. 2
- In vitro studies confirm rapid and potent P-gp inhibition in brain endothelial cells, as measured by increased cellular calcein accumulation. 2
- Chronic exposure (4 hours) to sertraline decreases P-gp-mediated efflux at the fetal BBB (P < 0.001), resulting in increased drug transfer into the fetal brain from circulation. 3
Placental Barrier Effects
- Sertraline increases placental P-gp-mediated efflux (P < 0.001) after 4-hour exposure, paradoxically resulting in decreased drug transfer to the fetus despite being a P-gp substrate itself. 3
- This demonstrates that P-gp regulation by sertraline is tissue-specific, with opposite effects at the placenta versus the BBB. 3
Clinical Implications
Drug-Drug Interactions
- Co-administration of sertraline with other P-gp substrates can significantly alter their CNS penetration through both competitive substrate effects and P-gp modulation. 1, 2
- The time-dependent nature of these effects means that acute versus chronic co-administration may produce different outcomes for CNS drug delivery. 2
Comparison to Other Antidepressants
- Unlike escitalopram, levomilnacipran, and vilazodone (which show 3.1-, 5.8-, and 5.4-fold increased brain exposure in P-gp knockout mice, respectively), sertraline's P-gp substrate status is confirmed but its clinical impact varies with exposure duration. 4
- Fluoxetine shows no significant P-gp interaction either in vitro or in vivo, distinguishing it from sertraline within the SSRI class. 2
Mechanistic Context
P-gp (also known as MDR-1 or ABCB1) is a 150-180 kDa membrane protein widely expressed at the luminal membrane of the BBB that protects the brain from hydrophobic molecules and drugs through ATP-dependent efflux. 5 Uncharged or weakly basic molecules like sertraline are most efficiently transported by P-gp. 5
Important Caveat
The in vitro P-gp efflux ratio can predict in vivo brain penetration regardless of BDDCS classification (r² = 0.813 for MDCK-MDR1 NIH cell line), meaning sertraline's P-gp substrate status has genuine clinical relevance for CNS penetration. 6